Compare CHCI & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCI | STXS |
|---|---|---|
| Founded | 1985 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.9M | 190.6M |
| IPO Year | 2004 | 2004 |
| Metric | CHCI | STXS |
|---|---|---|
| Price | $15.98 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 9.0K | ★ 369.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $62,861,000.00 | $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | $176.44 | ★ N/A |
| Revenue Growth | ★ 22.55 | N/A |
| 52 Week Low | $9.73 | $1.70 |
| 52 Week High | $19.72 | $3.59 |
| Indicator | CHCI | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 44.79 |
| Support Level | $15.24 | $1.73 |
| Resistance Level | $17.35 | $1.99 |
| Average True Range (ATR) | 0.93 | 0.09 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 87.72 | 18.57 |
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.